Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Rebecca Ibrahim,Khalil Saleh,Rita Khoury,Nadine Khalife,Claude Chahine,Axel Le Cesne
DOI: https://doi.org/10.2217/fon-2023-0523
2024-01-10
Future Oncology
Abstract:Keywords: cldn 18.2 gastric cancer gastro-esophageal carcinoma HER2 nivolumab targeted therapy zolbetuximab References 1. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 . Lancet Gastroenterol. Hepatol. 5(1), 42–54 ( 2020 ).Medline Google Scholar 2. Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up . Ann. Oncol. 33(10), 1005–1020 ( 2022 ).Medline CAS Google Scholar 3. Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial . Lancet 398(10294), 27–40 ( 2021 ).Medline CAS Google Scholar 4. Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial . Lancet 376(9742), 687–697 ( 2010 ).Medline CAS Google Scholar 5. Gómez-Martin C, Garralda E, Echarri MJ et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer . J. Clin. Pathol. 65(8), 751–757 ( 2012 ).Medline Google Scholar 6. Janjigian YY, Werner D, Pauligk C et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis . Ann. Oncol. 23(10), 2656–2662 ( 2012 ).Medline Google Scholar 7. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer . N. Engl. J. Med. 382(25), 2419–2430 ( 2020 ).Medline CAS Google Scholar 8. Janjigian YY, Kawazoe A, Yañez P et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer . Nature 600(7890), 727–730 (<span class="references__year -Abstract Truncated-
oncology
What problem does this paper attempt to address?